联合用药治疗便秘型肠易激综合征的临床疗效分析

摘要

Objective To explore the clinical efficacy of lactulose oral solution combined with kangfuxin and mosapride in treating constipation-predominant irritable bowel syndrome (IBS-C). Methods 60 IBS-C patients treated in our hospital were randomly divided into two groups, with 30 cases in each group. The control group was treated with mosapride, the experimental group was treated with lactulose oral solution combined with kangfuxin and mosapride. The clinical treatment effect, conditions of defecation and recurrence were compared between two groups. Results The total effective rate of experimental group was 96.67%, higher than 70.00%of control group, P<0.05. The defection times in a week, score of difficult defecation and stool character in experimental group were better than those in control group, P<0.05. The recurrence rate within six months after treatment in experimental group was 6.67%, lower than 33.33%in control group, P<0.05. Conclusions Lactulose oral solution combined with kangfuxin and mosapride has significant treatment effect in treating IBS-C, and can relieve patients' symptoms, improve bowel conditions and reduce recurrence.%目的：探讨采用乳果糖口服液、康复新联合莫沙必利治疗便秘型肠易激综合征（IBS-V)的临床疗效。方法选取在我院接受治疗的60例便秘型肠易激综合征患者作为研究对象，将其随机分为两组各30例。对照组患者采用莫沙必利治疗，试验组患者采用乳果糖口服液、康复新联合莫沙必利治疗。对比分析两组患者临床治疗效果、排便情况和复发情况。结果试验组患者临床总有效率明显高于对照组（96.67％vs 70.00％， P<0.05)。试验组患者治疗后每周大便次数、排便困难积分、大便性状积分均明显优于对照组， P<0.05。试验组治疗后半年内复发率明显低于对照组（6.67％vs 33.33％， P<0.05)。结论对肠易激综合征便秘型发作患者，采用乳果糖口服液、康复新联合莫沙必利治疗效果显著，可缓解患者症状，改善排便状况，较少复发。